Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 20/20 | 0.56 |
| ▸ | GABRB2 | P47870 | 20/20 | 0.56 |
| ▸ | GABRD | O14764 | 19/20 | 0.56 |
| ▸ | GABRA4 | P48169 | 19/20 | 0.56 |
| ▸ | GABRP | O00591 | 18/20 | 0.56 |
| ▸ | GABRB1 | P18505 | 18/20 | 0.56 |
| ▸ | GABRG2 | P18507 | 18/20 | 0.56 |
| ▸ | GABRB3 | P28472 | 18/20 | 0.56 |
| ▸ | GABRA5 | P31644 | 18/20 | 0.56 |
| ▸ | GABRA3 | P34903 | 18/20 | 0.56 |
| ▸ | GABRA2 | P47869 | 18/20 | 0.56 |
| ▸ | GABRE | P78334 | 18/20 | 0.56 |
| ▸ | GABRA6 | Q16445 | 18/20 | 0.56 |
| ▸ | GABRG1 | Q8N1C3 | 18/20 | 0.56 |
| ▸ | GABRG3 | Q99928 | 18/20 | 0.56 |
| ▸ | GABRQ | Q9UN88 | 18/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28461274 | 1.00 | GABRA1 (0.56) | GABRA1GABRB2GABRDGABRA4GABRP | |
| SCHEMBL29904114 | 0.97 | GABRA1 (0.56) | GABRA1GABRB2GABRDGABRA4GABRP | |
| SCHEMBL21618945 | 0.92 | GABRA1 (0.62) | GABRA1GABRB2GABRDGABRA4GABRP | |
| SCHEMBL16190893 | 0.92 | GABRA1 (0.62) | GABRA1GABRB2GABRDGABRA4GABRP | |
| SCHEMBL21265474 | 0.87 | GABRA1 (0.56) | GABRA1GABRB2GABRDGABRA4GABRP | |
| SCHEMBL29904062 | 0.86 | GABRA1 (0.55) | GABRA1GABRB2GABRDGABRA4GABRP | |
| SCHEMBL31602927 | 0.86 | GABRA1 (0.55) | GABRA1GABRB2GABRDGABRA4GABRP | |
| SCHEMBL28457335 | 0.86 | GABRD (0.53) | GABRA1GABRB2GABRDGABRA4GABRP | |
| SCHEMBL28455500 | 0.86 | GABRD (0.53) | GABRA1GABRB2GABRDGABRA4GABRP | |
| SCHEMBL22576792 | 0.85 | GABRA1 (0.54) | GABRA1GABRB2GABRDGABRA4GABRP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3728285-B1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS LLC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20250171492-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-20220315621-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. | 2022-10-06 | — | — | US | disclosed |
| CN-111741965-A | Compositions and methods for treating central nervous system disorders | 萨奇治疗股份有限公司 | 2020-10-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171492-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | ATP6V1B2, RAB9A, GRIN2B | GABRA1 960/4885GABRB2 703/4885GABRD 3073/4885 |
| US-20220315621-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | ATP6V1B2, RAB9A, GRIN2B | GABRA1 960/4885GABRB2 703/4885GABRD 3073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.